Ginkgo Bioworks Holdings, Inc., a company incorporated in Delaware and listed on the NYSE under the symbol DNA, has reported a change in its independent registered public accounting firm. The company's Audit Committee initiated a request-for-proposal process on February 1, 2024, to select a new auditor for the fiscal year ending December 31, 2024. Ernst & Young LLP (EY), the company's previous auditor, declined to stand for re-appointment on March 8, 2024, a decision that was not due to any disagreements with the company. On March 13, 2024, the Audit Committee appointed Deloitte & Touche LLP (Deloitte) as the new auditor. EY's reports on the company's financial statements for the fiscal years ended December 31, 2023, and 2022 were unqualified. However, EY identified material weaknesses in...Show More

Ginkgo Bioworks Holdings, Inc., a company incorporated in Delaware and listed on the NYSE under the symbol DNA, has reported a change in its independent registered public accounting firm. The company's Audit Committee initiated a request-for-proposal process on February 1, 2024, to select a new auditor for the fiscal year ending December 31, 2024. Ernst & Young LLP (EY), the company's previous auditor, declined to stand for re-appointment on March 8, 2024, a decision that was not due to any disagreements with the company. On March 13, 2024, the Audit Committee appointed Deloitte & Touche LLP (Deloitte) as the new auditor. EY's reports on the company's financial statements for the fiscal years ended December 31, 2023, and 2022 were unqualified. However, EY identified material weaknesses in internal control over financial reporting for both years. The company has discussed these issues with EY and has authorized them to respond to Deloitte's inquiries regarding the matter. The transition of auditors has been disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission, which includes a letter from EY agreeing with the statements made in the report.